1820 McCarthy Blvd.
Milpitas
CA
95035
USA
408.273.3700
Cordis, a Cardinal Health company, is a worldwide leader in the development and manufacture of interventional vascular technology with a more than 50-year history of delivering pioneering products to treat millions of patients.
Related Content
Feature | Mark Paquin
April 15, 2012, will mark the 10th anniversary of the approval of the first drug-eluting stent (DES). Ten years ago, the ...
March 16, 2012
January 23, 2012 โ Boston Scientific Corp. said the U.S. District Court for the District of New Jersey has found all the ...
January 24, 2012
Feature | Dave Fornell
There have been several key news items from the U.S. stent market over the past year. These include the introduction of ...
September 26, 2011
Feature | By Karene Dumoulin, Principal Analyst, Millennium Research Group
Navigating through the world of coronary stents is about to become more complex. A plethora of new products are on the ...
July 15, 2011
June 16, 2011 โ Johnson & Johnson subsidiary Cordis International announced Wednesday that it will cease production of ...
June 16, 2011May 16, 2011 - Cordis announces the launch in Europe of Radial Solutions, a complete portfolio for transradial ...
May 16, 2011
Feature | Dave Fornell
The start-up company Corindus for several years has been developing a robotic-assist system for use in the cardiac cath ...
April 21, 2011
January 27, 2011 โ The U.S. Food and Drug Administration (FDA) granted conditional investigational device exemption (IDE ...
January 27, 2011
December 6, 2010 โ Cordis Corp. has entered into a distribution agreement with Ostial Solutions for the worldwide ...
December 06, 2010
May 26, 2010 โ The 12-month study results for a drug-eluting stent that uses hundreds of tiny holes, filled with ...
May 26, 2010ยฉ Copyright Wainscot Media. All Rights Reserved.
Subscribe Now